Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acalisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 16/20 | 0.77 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.77 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.77 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.60 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acalisib SCHEMBL356540 | 1.00 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| Acalisib SCHEMBL29422834 | 1.00 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| Acalisib SCHEMBL16677409 | 1.00 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| Acalisib SCHEMBL29360030 | 1.00 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| SCHEMBL16677731 | 0.95 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| SCHEMBL16677771 | 0.95 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| SCHEMBL16677429 | 0.95 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| SCHEMBL356432 | 0.95 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| SCHEMBL16677730 | 0.95 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 | |
| SCHEMBL16677435 | 0.95 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3C3PIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | claimed |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-01-25 | — | — | US | claimed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | claimed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| US-20220241281-A1 | Imidazopyrimidine Derivatives | GILEAD SCIENCES, INC. | 2022-08-04 | — | — | US | claimed |
| WO-2021226262-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | claimed |
| EP-3873903-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | claimed |
| WO-2020237025-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-11-26 | — | — | WO | claimed |
| US-20160331754-A1 | THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES INC (US) | 2016-11-17 | — | — | US | claimed |
| US-20160279135-A1 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS | GILEAD SCIENCES INC (US) | 2016-09-29 | — | — | US | claimed |
| US-20150148345-A1 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS | GILEAD SCIENCES, INC, | 2015-05-28 | — | — | US | claimed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | TWELVE THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | ICOS CORPORATION (US) | 2008-11-06 | — | — | US | disclosed |
| EP-1761540-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005113554-A2 | METHOD OF PREPARING 3-PHENYL-2-[9H-PURIN-6-YLAMINO)-METHYL]-3H-QUINAZOLIN-4-ONE AND SUBSTITUTED AND RELATED COMPOUNDS | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113556-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241281-A1 | Imidazopyrimidine Derivatives | DPYD, KRAS, ABL1 | PIK3CD 154/4885PIK3CG 433/4885PIK3C3 905/4885 |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | PIK3CD 13/4885PIK3CG 56/4885PIK3C3 77/4885 |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | PIK3CD 3/4885PIK3CG 9/4885PIK3C3 4/4885 |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | PIK3CD 2727/4885PIK3CG 3429/4885PIK3C3 2250/4885 |
| US-20150148345-A1 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS | MPL, ETV6, JAK2 | PIK3CD 1582/4885PIK3CG 1321/4885PIK3C3 471/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | PIK3CD 2727/4885PIK3CG 3429/4885PIK3C3 2250/4885 |
| US-20240025923-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, HIPK2 | PIK3CD 2395/4885PIK3CG 2700/4885PIK3C3 1607/4885 |
| US-20160331754-A1 | THERAPIES FOR TREATING CANCERS | JAK2, JAK1, THPO | PIK3CD 22/4885PIK3CG 10/4885PIK3C3 20/4885 |
| US-20160279135-A1 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS | MPL, ETV6, JAK2 | PIK3CD 1582/4885PIK3CG 1321/4885PIK3C3 471/4885 |
| US-20080275067-A1 | Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3C3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.